Therapeutic pattern and progress of neoadjuvant treatment for triple‑negative breast cancer (Review)

Yan, Xin; Gao, Wen-Cheng

doi:10.3892/ol.2022.13340

Cited by 4 publications

(3 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNBC is characterized by being more aggressive and sensitive to cytotoxic drugs. Although pCR is closely associated with a favorable long-term prognosis, TNBC is still more likely to relapse and metastasize during early follow-up, due to the lack of specific therapeutic targets to control tumor growth, especially among patients who do not achieve pCR [ 38 ]. In addition, a higher proportion of patients in the HER2-0 group had increased HER2 IHC score after NACT, suggesting that the tumors of these patients were more likely to express HER2 gene or protein after chemotherapy, which might accelerate tumor recurrence and metastasis.…”

Section: Discussionmentioning

confidence: 99%

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

et al. 2022

View full text Add to dashboard Cite

Purpose Low expression of HER2 (HER2-low expression) in breast cancer (BC) has unique biological characteristics. However, whether HER2-low expression has an impact on neoadjuvant chemotherapy (NACT) in HER2-negative breast cancer remains unclear. Methods This study reviewed the clinicopathological data of patients with BC treated with NACT at a single hospital from January 2018 to July 2022. Baseline patient characteristics, efficacy of NACT, and survival data were compared between the HER2-0 and HER2-low groups. The impact of NACT on HER2 status also was investigated. Subgroup analyses based on hormone receptor (HR) status were performed to explore the impact of HR signaling on HER2 status during chemotherapy. Results The progesterone receptor-positive rate in the HER2-low group was significantly higher than that in HER2-0 group. The local treatment response of the HER2-low group was worse, but the disease-free survival rate of the HER2-low group was significantly better than that of the HER2-0 group. The proportion of patients with increased HER2 immunohistochemistry score after NACT was significantly higher in the HER2-0 group. Subgroup analysis showed that the efficacy of chemotherapy in HR + patients was significantly worse than in HR− patients, and HR + patients had a higher proportion of increased HER2 immunohistochemistry score after chemotherapy. Mechanistic studies suggested that MLH1 expression loss during chemotherapy might link HR signaling and regulation of HER2 expression. Conclusions We found that HER2-low expressing BC exhibits differential sensitivity to chemotherapy compared to HER2-0 expressing BC. The regulation of HER2 expression by HR signaling may mediate aspects of chemoresistance.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…TNBC is with a heterogeneous tumor structure, exhibits different biological behaviors, and has multiple molecular subtypes, which has been an important issue for researchers in recent years to plan treatment and develop new treatments. Recent studies show that there are significant differences in treatment strategies between different subtypes of breast cancer cases [ 2 , 3 ]. One of the most important problems encountered in chemotherapy and radiotherapy treatment is that the tumor tissue does not respond to treatment at all or less.…”

Section: Introductionmentioning

confidence: 99%

The effect of silencing the Tip60 gene on the response to radiotherapy in breast cancer cells

Miser-Salihoglu¹,

Karahalıl²,

Eşmakaya³

et al. 2023

The Breast

View full text Add to dashboard Cite

“…However, according to clinical statistics, the overall response rate (ORR‘) of mTNBC with single-agent chemotherapy is only 10–30%, and with the best multi-drug combination chemotherapy regimen it is only 63%. The average pathologically complete response (pCR) to mTNBC with multi-drug combination chemotherapy regimen is about 30–40% [ 3 ]. In summary, the benefit of chemotherapy for patients with mTNBC is not promising [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

Ren

Song

Luo

2022

IJMS

View full text Add to dashboard Cite

Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.

show abstract

Therapeutic pattern and progress of neoadjuvant treatment for triple‑negative breast cancer (Review)

Cited by 4 publications

References 86 publications

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

The effect of silencing the Tip60 gene on the response to radiotherapy in breast cancer cells

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

Contact Info

Product

Resources

About